Watch for Xanomeline/Trospium to Treat Schizophrenia
January 2025
You’ll notice patients come in on xanomeline/trospium (Cobenfy), the first in a new class of drugs approved to treat schizophrenia in decades.
Schizophrenia is mostly treated with antipsychotics (olanzapine, quetiapine, etc) that block dopamine and serotonin receptors in the brain.
Xanomeline/trospium works on completely different receptors in the brain to help target symptoms (hallucinations, delusions, etc).
Practical advice for a better career, with unlimited access to CE
Hospital Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote